AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17269594 — intervention group
Group type: COMPARATOR
Intervention: Calcitriol
Number of subjects: 31
Study 16236142 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous corticosteroid therapy (500 mg intravenous methylprednisolone daily)
Number of subjects: 65
Study 16236142 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral corticosteroid therapy (1 mg/kg oral prednisolone daily)
Number of subjects: 65
Study 16236142 — intervention group
Group type: COMPARATOR
Intervention: Intravenous corticosteroid therapy
Number of subjects: 65
Study 12043317 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with overweight (BMI > 26 kg/m2)
Number of subjects: 31
Study 12043317 — intervention group
Group type: COMPARATOR
Intervention: Control group (hypertensives with normal weight)
Number of subjects: 31
Study 10207780 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg, Amoxycillin 1.0 g, Metronidazole 400 mg (12 h post-treatment)
Number of subjects: 28
Study 10207780 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (0 h)
Number of subjects: 28
Study 8563457 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine (alpha-receptor agonist)
Number of subjects: 1
Study 8563457 — intervention group
Group type: COMPARATOR
Intervention: Disopyramide
Number of subjects: 1
Study 19256157 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 5
Study 19256157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 1122828 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine, chlormethine, procarbazine and prednisone (protocol H2‐65) for six months, followed by monthly vinblastine injections.
Number of subjects: 204
Study 1122828 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine, chlormethine, procarbazine and prednisone (protocol H2‐65) with additional prophylactic radiotherapy.
Number of subjects: 204
Study 1122828 — intervention group
Group type: COMPARATOR
Intervention: Vincristine, chlormethine, procarbazine and prednisone (protocol H2‐65) without radiotherapy.
Number of subjects: 204
Study 1122828 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine, chlormethine, procarbazine and prednisone (protocol H2‐65) with reinduction treatment.
Number of subjects: 204
Study 31107710 — intervention group
Group type: EXPERIMENTAL
Intervention: Fovea‐sparing internal limiting membrane peeling (Group S)
Number of subjects: 36
Study 31107710 — intervention group
Group type: COMPARATOR
Intervention: Observation only (Group C)
Number of subjects: 36
Study 31476701 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex karyotype (CK)
Number of subjects: 644
Study 31476701 — intervention group
Group type: COMPARATOR
Intervention: No complex karyotype (CK)
Number of subjects: 644
Study 31476701 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with aberrations of TP53 and ATM
Number of subjects: 644
Study 31476701 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex karyotype (CK) in female and older CLL patients
Number of subjects: 644
Study 28478481 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ω-3 fatty acids and nano-curcumin
Number of subjects: 74
Study 28478481 — intervention group
Group type: COMPARATOR
Intervention: ω-3 fatty acids alone
Number of subjects: 74
Study 28478481 — intervention group
Group type: COMPARATOR
Intervention: nano-curcumin alone
Number of subjects: 74
Study 28478481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 25159605 — intervention group
Group type: EXPERIMENTAL
Intervention: Total laparoscopic hysterectomy (TLH) group
Number of subjects: 99
Study 25159605 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal hysterectomy (TVH) group
Number of subjects: 99
Study 25159605 — intervention group
Group type: COMPARATOR
Intervention: Transabdominal hysterectomy (TAH) group
Number of subjects: 99
Study 25159605 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified lithotomy position (TLH group)
Number of subjects: 99
Study 25159605 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional lithotomy position (TVH group)
Number of subjects: 99
Study 22661646 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous golimumab 2 mg/kg + methotrexate (MTX)
Number of subjects: 592
Study 22661646 — intervention group
Group type: COMPARATOR
Intervention: Placebo + methotrexate (MTX)
Number of subjects: 592
Study 21275850 — intervention group
Group type: EXPERIMENTAL
Intervention: RAC (7.5 mg over 1 hour)
Number of subjects: 99
Study 21275850 — intervention group
Group type: COMPARATOR
Intervention: LEV (3.75 mg over 1 hour)
Number of subjects: 99
Study 21275850 — intervention group
Group type: COMPARATOR
Intervention: RAC and LEV
Number of subjects: 99
Study 20110023 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 642
Study 20110023 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 642
Study 20110023 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 75 mg
Number of subjects: 642
Study 20110023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 642
Study 16901950 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT), 40 sessions
Number of subjects: 85
Study 16901950 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 85
Study 15136378 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 200 microg (400 microg/d) plus Zafirlukast 20 mg bid
Number of subjects: 49
Study 15136378 — intervention group
Group type: COMPARATOR
Intervention: Budesonide 600 microg bid (1,200 microg/d)
Number of subjects: 49
Study 11091168 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose citrate anticoagulation (60 IU heparin/kg body weight as initial bolus; 1:40 ACD‐A: blood as perfusion)
Number of subjects: 5
Study 11091168 — intervention group
Group type: COMPARATOR
Intervention: Standard anticoagulation regimen (20 IU heparin/kg bolus; 1:20 ACD‐A as perfusion)
Number of subjects: 5
Study 9135702 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (PD, 120 mg, orally)
Number of subjects: 11
Study 9135702 — intervention group
Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 11
Study 9135702 — intervention group
Group type: EXPERIMENTAL
Intervention: PD plus exercise
Number of subjects: 11
Study 9135702 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-6 (100 micrograms, i.v.)
Number of subjects: 11
Study 9135702 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-6 plus exercise
Number of subjects: 11
Study 8445463 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% sodium hyaluronate in physiologic saline
Number of subjects: 121
Study 8445463 — intervention group
Group type: COMPARATOR
Intervention: USP physiologic saline
Number of subjects: 121
Study 3524842 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine (10 mg IV)
Number of subjects: 56
Study 3524842 — intervention group
Group type: COMPARATOR
Intervention: Meperidine (50 mg IV)
Number of subjects: 56
Study 31674216 — intervention group
Group type: EXPERIMENTAL
Intervention: CARE Plus intervention
Number of subjects: 14
Study 28641022 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitnox (250 mg capsule as single dose)
Number of subjects: 24
Study 28641022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 27579772 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual-level plus structural-level intervention (Arm 4)
Number of subjects: 136
Study 27579772 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (Arm 1)
Number of subjects: 136
Study 24339297 — intervention group
Group type: EXPERIMENTAL
Intervention: Havrix
Number of subjects: 451
Study 24339297 — intervention group
Group type: EXPERIMENTAL
Intervention: Epaxal
Number of subjects: 451
Study 22498110 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK573719 once-daily doses (62.5-1000 μg)
Number of subjects: 176
Study 22498110 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK573719 twice-daily doses (62.5-250 μg)
Number of subjects: 176
Study 22498110 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (open-label)
Number of subjects: 176
Study 20054739 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin supplementation (1000 mg x day(‐1))
Number of subjects: 11
Study 20054739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 18617310 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconferencing instruction
Number of subjects: 0
Study 18617310 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face instruction
Number of subjects: 0
Study 16172619 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal replacements (MR)
Number of subjects: 55
Study 16172619 — intervention group
Group type: COMPARATOR
Intervention: Control (C) - structured eating plan
Number of subjects: 55
Study 16172619 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MR and C
Number of subjects: 55
Study 12427189 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline solution administered prior to endotracheal suctioning
Number of subjects: 20
Study 12427189 — intervention group
Group type: COMPARATOR
Intervention: Suctioning without saline solution
Number of subjects: 20
Study 10617250 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 1 mg/NGM 90 microg
Number of subjects: 1253
Study 10617250 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 1 mg/NGM 30 microg
Number of subjects: 1253
Study 10617250 — intervention group
Group type: COMPARATOR
Intervention: E2 1 mg
Number of subjects: 1253
Study 8950450 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable screws and rods
Number of subjects: 37
Study 8950450 — intervention group
Group type: COMPARATOR
Intervention: Metallic implants
Number of subjects: 37
Study 8950450 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 37
Study 1958437 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg three times daily
Number of subjects: 8
Study 1958437 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (no nifedipine)
Number of subjects: 8
Study 1958437 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 8
Study 6752331 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinoxacin
Number of subjects: 59
Study 6752331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 31880964 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab 3 mg/kg (ipi3)
Number of subjects: 1670
Study 31880964 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab 10 mg/kg (ipi10)
Number of subjects: 1670
Study 31880964 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Dose Interferon Alfa-2b (HDI)
Number of subjects: 1670
Study 31299242 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy
Number of subjects: 43
Study 31299242 — intervention group
Group type: COMPARATOR
Intervention: 3-dimensional chemoradiation therapy
Number of subjects: 43
Study 28900520 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 0
Study 28900520 — intervention group
Group type: COMPARATOR
Intervention: Physical Examination (PEx)
Number of subjects: 0
Study 25829048 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (40 mg.kg(‐1))
Number of subjects: 73
Study 25829048 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 73
Study 24043677 — intervention group
Group type: EXPERIMENTAL
Intervention: 23 to 32 mm Hg (moderate) compression stocking treatment
Number of subjects: 100
Study 24043677 — intervention group
Group type: EXPERIMENTAL
Intervention: 34 to 46 mm Hg (high) compression stocking treatment
Number of subjects: 100
Study 24043677 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to treatment
Number of subjects: 100
Study 21642014 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg subcutaneously at weeks 0, 2, and 4
Number of subjects: 439
Study 21642014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 439
Study 21642014 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 439
Study 19806184 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01(E)
Number of subjects: 19
Study 19806184 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS02(D)
Number of subjects: 19
Study 19806184 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01(E) and RTS,S/AS02(D)
Number of subjects: 19
Study 19806184 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 dose schedules
Number of subjects: 19
Study 19806184 — intervention group
Group type: COMPARATOR
Intervention: RTS,S/AS01(E) (0,1,2-month schedule)
Number of subjects: 19
Study 19806184 — intervention group
Group type: COMPARATOR
Intervention: RTS,S/AS01(E) and rabies vaccine
Number of subjects: 19
Study 16276359 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Hunters intervention program focusing on food choice, physical activity, and lifestyle factors
Number of subjects: 40
Study 16276359 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 40
Study 16276359 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Hunters intervention program
Number of subjects: 40
Study 15067028 — intervention group
Group type: EXPERIMENTAL
Intervention: FU + leucovorin or FU + levamisole
Number of subjects: 3302
Study 15067028 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 3302
Study 15067028 — intervention group
Group type: EXPERIMENTAL
Intervention: FU-based therapy
Number of subjects: 3302
Study 11742269 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal Steroid (NS) - budesonide 400 microg daily
Number of subjects: 41
Study 11742269 — intervention group
Group type: COMPARATOR
Intervention: Specific Immunotherapy (SIT)
Number of subjects: 41
Study 9338418 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (Seranace, 0.05 mg/kg)
Number of subjects: 15
Study 9338418 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 15
Study 7509325 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5-5 mg once daily
Number of subjects: 32
Study 7509325 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25-50 mg once daily
Number of subjects: 32
Study 7509325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 3771292 — intervention group
Group type: EXPERIMENTAL
Intervention: Mashed potatoes
Number of subjects: 11
Study 3771292 — intervention group
Group type: EXPERIMENTAL
Intervention: Polished rice
Number of subjects: 11
Study 3771292 — intervention group
Group type: EXPERIMENTAL
Intervention: Mashed white beans
Number of subjects: 11
Study 28539351 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT)
Number of subjects: 24
Study 28539351 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 24
Study 27280367 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirming implementation intention added to standard labeling
Number of subjects: 143
Study 27280367 — intervention group
Group type: COMPARATOR
Intervention: Standard labeling
Number of subjects: 143
Study 26643818 — intervention group
Group type: EXPERIMENTAL
Intervention: Group rehabilitation intervention plus usual care
Number of subjects: 400
Study 26643818 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 400
Study 23716745 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized patients
Number of subjects: 80
Study 23716745 — intervention group
Group type: COMPARATOR
Intervention: Manikins
Number of subjects: 80
Study 20962899 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride (10 mg)
Number of subjects: 10
Study 20962899 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg)
Number of subjects: 10
Study 20962899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 18947475 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhu‐EPO treatment (250 IU/kg, 3 times weekly for 4 weeks)
Number of subjects: 44
Study 18947475 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhu‐EPO treatment
Number of subjects: 44
Study 15714171 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose tacrolimus (0.075 mg/kg/day)
Number of subjects: 113
Study 15714171 — intervention group
Group type: COMPARATOR
Intervention: High-dose tacrolimus (0.15 mg/kg/day)
Number of subjects: 113
Study 12842526 — intervention group
Group type: EXPERIMENTAL
Intervention: Total surface-heparinized circuits (Group B, n = 52)
Number of subjects: 159
Study 12842526 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface heparinization limited to oxygenator and arterial filter (Group C, n = 56)
Number of subjects: 159
Study 12842526 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group A, n = 51)
Number of subjects: 159
Study 11006056 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder letter from physician (Group 1)
Number of subjects: 1562
Study 11006056 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder letter from mammography facility (Group 2)
Number of subjects: 1562
Study 11006056 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 3)
Number of subjects: 1562
Study 11824001 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteplase
Number of subjects: 6010
Study 11824001 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 6010
Study 1290620 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg, 100 mg, 150 mg
Number of subjects: 0
Study 1290620 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 10 mg, 25 mg
Number of subjects: 0
Study 1290620 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once daily
Number of subjects: 0
Study 1290620 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (various doses)
Number of subjects: 0
Study 1290620 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0
Study 6742256 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-monitored blood pressure cuffs
Number of subjects: 396
Study 6742256 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitored blood pressure cuffs
Number of subjects: 396
Study 6742256 — intervention group
Group type: COMPARATOR
Intervention: No cuff (control group)
Number of subjects: 396
Study 30860001 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine extended-release oral suspension (AMPH EROS)
Number of subjects: 108
Study 30860001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 29739965 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Ageing Nutrition Index (HANI) for men
Number of subjects: 1898
Study 29739965 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Ageing Nutrition Index (HANI) for women
Number of subjects: 1898
Study 26198386 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-week group-based multidisciplinary programme of task-oriented exercises integrated with cognitive behavioural therapy
Number of subjects: 150
Study 26198386 — intervention group
Group type: COMPARATOR
Intervention: Group-based traditional exercises
Number of subjects: 150
Study 24460589 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone application
Number of subjects: 125
Study 24460589 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidulated phosphate fluoride gel
Number of subjects: 125
Study 24460589 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP-ACP-containing material (Tooth Mousse)
Number of subjects: 125
Study 24460589 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial bonding agent (Clearfil Protect Bond)
Number of subjects: 125
Study 24460589 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 125
Study 23251374 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe traumatic bleeding
Number of subjects: 20127
Study 23251374 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing age, decreasing systolic blood pressure, increased respiratory rates, longer central capillary refill times, higher heart rates, lower Glasgow Coma Scores
Number of subjects: 20127
Study 23251374 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted risk of hemorrhage death
Number of subjects: 20127
Study 19582491 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (levo)
Number of subjects: 600
Study 19582491 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 600
Study 18187427 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzymatically processed beta-glucan (Oat-A)
Number of subjects: 11
Study 18187427 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat-A
Number of subjects: 11
Study 18187427 — intervention group
Group type: COMPARATOR
Intervention: Oat-B
Number of subjects: 11
Study 18187427 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 11
Study 16238998 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic dissector
Number of subjects: 0
Study 16238998 — intervention group
Group type: COMPARATOR
Intervention: Traditional methods
Number of subjects: 0
Study 11904656 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype face mask (PM)
Number of subjects: 47
Study 11904656 — intervention group
Group type: COMPARATOR
Intervention: Conventional masks (CMs)
Number of subjects: 47
Study 9459240 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mL of propofol (n = 17)
Number of subjects: 29
Study 9459240 — intervention group
Group type: COMPARATOR
Intervention: 1 mL of placebo (n = 12)
Number of subjects: 29
Study 7658953 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cardiac rehabilitation lasting 8 weeks
Number of subjects: 187
Study 7658953 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 187
Study 2561144 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg benazepril orally once a day for 2 days
Number of subjects: 10
Study 2561144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30183398 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (VC) supplementation 300 mg per day for 6 months
Number of subjects: 0
Study 30183398 — intervention group
Group type: COMPARATOR
Intervention: Control group (nothing)
Number of subjects: 0
Study 28199556 — intervention group
Group type: EXPERIMENTAL
Intervention: Perventricular device closure (PVDC)
Number of subjects: 640